MedTrace Logo

Brain Effects of Escitalopram and Citalopram Using fMRI

NCT00825825 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-07-14

Study results available
· View outcomes & findings →

Summary

Escitalopram (Lexapro) and citalopram (Celexa) are similar selective serotonin reuptake inhibitors that alter blood flow to the amygdala and other brain structures involved in regulating mood. Escitalopram consists of S-citalopram while citalopram contains both S-citalopram and R-citalopram (racemic citalopram). There is evidence that R-citalopram may block the effects of S-citalopram. The hypothesis being tested is that because of the antagonist effect of R-citalopram, S-citalopram will have a greater effect on the mood circuit than racemic citalopram when equal doses of S-citalopram are administered. The study design consists of a two week medication period followed by blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) while viewing affective visual stimuli.

Conditions

  • Antidepressant Activity in Healthy Volunteers

Interventions

DRUG

Escitalopram

One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.

DRUG

Citalopram

One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.

DRUG

Placebo

Two weeks of placebo taken orally.

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Michael Henry, MD

    lead OTHER

Principal Investigators

  • Michael E Henry, MD · Steward St. Elizabeth's Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825825 on ClinicalTrials.gov